查詢結果分析
來源資料
相關文獻
- Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer: An Asian Single Institute Experience
- 圈養亞洲公象狂暴期行為研究
- 亞洲空罐市場令人樂觀
- 亞洲金融風暴對我國出口衝擊之評估
- 由1998臺北雙年展:漫談亞洲當代藝術的未來--亞洲當代藝術的未來,在期待的,當然是亞洲當代的藝術家
- 亞洲當代藝術:傳統與張力
- 文化差異與多元文化主義--「亞洲當代藝術:傳統與張力」
- 亞洲ABS樹脂近況
- 臺灣在亞洲金融風暴中的經驗--回顧與展望
- 亞洲金融風暴觀察重點
頁籤選單縮合
題 名 | Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer: An Asian Single Institute Experience=以誘導式化療Docetaxel, Cisplatin和5-Fluorouracil治療局部晚期頭頸癌:單一亞洲醫學中心的經驗 |
---|---|
作 者 | 周益聖; 朱本元; 戴世光; 蔡東龍; 王怡芬; 許彥彬; 李宗倫; 陳明晃; 曾成槐; 張牧新; 楊慕華; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 26:2 2010.04[民99.04] |
頁 次 | 頁55-64 |
分類號 | 416.21 |
關鍵詞 | 歐洲紫杉醇; 頭頸癌; 亞洲; Docetaxel; Head and neck cancer; Asian; |
語 文 | 英文(English) |
中文摘要 | 背景:此回溯性研究為探討,使用引導化學治療(induction chemotherapy)來治療局部晚期 頭頸癌(locally advanced head and neck cancer),包含docetaxel, cisplatin 和5-fluorouracil。 此研究的目的是此化療使用在亞洲族群的療效,存活率,及副作用。 方法:共33 個頭頸癌病人,其癌症期別為第三與四期,活動功能介於ECOG 0 至2 之間。 使用的劑量為 Docetaxel 60mg/m2, cisplatin 75mg/m2 而 5-fluourocil 850mg/m2 連續給予 4 天。 每三個禮拜給予一次化療,最多給予共三次化療。Kaplan-Meier 存活曲線用來評 估存活率。使用RECIST version 1.1 和the expanded common toxicity criteria of the Clinical Trials Group of the National Cancer Institute of Canada 評估反應率(response rates) 和化療毒 性(toxicity)。 結果:完全反應率(complete response rate) 9.1%,部份反應率( partial response rate) 66.7%, 疾病穩定率9.1%,而病情惡化率9.1%。一年整體存活率(overall survival rate)為93%,一 年無進展存活率(progression free survival)為71.4%。共有20 個病人(60.6%)有超過第三級 血液毒性(hematologic toxicity)。在這二十個曾經發生中性球低下的病人中,有七個人有發 燒,三個病人有急性腎衰竭。 結論:Docetaxel, cisplatin 和5-fluorouracil 作為治療局部進展頭頸癌的引導化學治療是有 效的。然而,中性球低下的發燒(febrile neutropenia)還是最重要的副作用,所以儘量避免 使用在超過70 歲的老人,或是提早使用白血球生長激素,使總白血球維持在2000/uL 或 許有幫助。 |
英文摘要 | Background: A retrospective analysis of treating locally advanced head and neck cancer with induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (TPF) among Taiwan patients. The purpose of this study was to report response rates, survival, and toxicity of induction chemotherapy with TPF among Asians. Methods: Thirty-three patients with stage III-IV head and neck cancer with good performance status (ECOG:0-2) were enrolled. Docetaxel 60 mg/m2, cisplatin 75 mg/m2, and 5-fluourocil 850 mg/m2 for 4 days were administered every 3 weeks to, at the most, 3 cycles. The Kaplan-Meier survival curve was used to assess survival rates. Response rates and toxicities were graded by RECIST version 1.1 and the expanded common toxicity criteria of the Clinical Trials Group of the National Cancer Institute of Canada. Results: The complete response rate after induction of TPF was 9.1%, partial response rate was 66.7%, and the rate of stable disease was 9.1%, while the rate of progressive disease was 9.1%. The one-year overall survival rate was 93%, and one-year progression-free survival rate was 71.4%. Hematologic toxicities greater than grade 3 were noted in a total of 20 patients (60.6%). Seven cases among the twenty neutropenia patients developed febrile neutropenia. Three patients had acute renal failure. Conclusions: This TPF regimen is effective in Asian patients as induction chemotherapy for locally advanced squamous cell carcinoma of head and neck. However, febrile neutropenia remains the most important consideration. Avoiding use in the elderly aged more than 70 years of age or early preventive GCSF to keep total WBC > 2000/uL be helpful. |
本系統中英文摘要資訊取自各篇刊載內容。